Sera from patients with motor neuron disease and associated paraproteinaemia fail to inhibit experimentally induced sprouting of motor nerve terminals MICHAEL DONAGHY, LW DUCHEN From the Departments ofNeurology and Neuropathology, Institute ofNeurology and The National Hospitalfor Nervous Diseases, London, UK SUMMARY IgG kappa paraproteinaemia was discovered in one patient with amyotrophic lateral sclerosis and one with chronic spinal muscular atrophy. Serum from these patients was injected into mouse muscles paralysed by botulinum toxin which is known to induce sprouting from motor nerve terminals. Daily injection of serum for 7 days failed to inhibit terminal sprouting. It is concluded that the paraproteins did not recognise a growth factor postulated as being implicated in the pathogenesis of motor neuron disease.
Injection of botulinum toxin (BoTx) into skeletal muscle causes motor nerve terminals to sprout.1 Such sprouting has been reported to be inhibited by subsequent injection of serum from patients with amyotrophic lateral sclerosis.2 It is possible that disorders of neuromuscular connectivity could be caused by autoantibodies to a growth factor which is normally secreted by muscle fibres and controls their innervation. A rare clinical association exists between paraproteinaemia and amyotrophic lateral sclerosis, spinal muscular atrophy or motor neuropathy.3 In such patients the paraprotein might possess autoantibody activity against a motor nerve growth factor. We have tested paraproteinaemic sera from two patients with disordered neuromuscular connectivity for their capacity to inhibit motor nerve terminal sprouting induced by BoTx in mouse soleus muscle.
Methods
Subjects Monoclonal gammopathies were detected by routine serum electrophoresis in two patients under investigation for neuromuscular disease. Fresh serum from these patients and a healthy human control without para-proteinaemia were stored frozen in 0 3 ml aliquots at -200C.
Animal experiments CFLP mice weighing 25-35 g were used. A single dose of 0 004 ug type A BoTx (Sigma) in 0 1 ml gelatin phosphate buffer was injected deep into the calf muscles of the right leg. Two hours later, and daily thereafter, 0 1 ml of serum was injected into the same site. Two animals were given BoTx alone, and the patients' or control sera were each given to four animals. All mice developed profound weakness of the right leg. After 7 days the mice were killed by intracardiac perfusion with 1% calcium acetate in 10% formalin under ether anaesthesia. The soleus muscle was immediately dissected out and fixed for 1 hour in calcium formalin solution at 40C before sectioning. It is known from previous work that sprouting from motor endplates is well established 7 days after BoTx injection into mouse soleus muscle.4 Histology Serial longitudinal 20pm frozen sections of the muscle were stained for cholinesterase activity and nerve fibres.5 Occasional sections were distorted or lost during sectioning. Slides were coded and subsequently examined "blind". Each motor end-plate was examined under high power and, if a preterminal axon was identified, the presence and number of terminal sprouts were recorded. 
Results
The histological appearance of sprouting nerve terminals is shown in the figure. End-plates were readily identified by the dense concentration of cholinesterase reaction product. Only end-plates whose preterminal axon was identifiable were included in this quantitative survey. At some end-plates, no sprouts could be seen in direct continuity with the end-plate but at others delicate axonal sprouts could be seen arising from terminals within the end-plates. These sprouts could be readily distinguished from the preterminal myelinated fibre by their calibre and the common occurrence of crystals of cholinesterase reaction product along them.
The table shows the proportion of end-plates from which sprouts were arising 7 days after injection with BoTx alone, BoTx and control serum, and BoTx and paraproteinaemic serum from patient 1 or patient 2. Although the proportion of terminals which had sprouted was similar in all groups, the muscles injected with. patients' sera contained a slightly larger number of sprouts per end plate than the control 1' w Fig Frozen sections ofmouse soleus stained to show end-plate cholinesterase and nerve fibres 7 days after injection of (A) BoTx and serum from patient with amyotrophic lateral sclerosis (B) BoTx and control serum. Infig 1(A) end-plates numbered 1, 2, and 3 show terminal sprouting whereas 4 does not. In fig I (B) only end-plate 3 shows sprouts, I and 2 do not, and 4 and 5 were not included in the counts since their preterminal axons were not seen. (Arrows to some sprouts) ( x 500) Motor neuron disease, paraproteinaemia and nerve sprouting Various explanations are possible for the failure of paraproteinaemic sera to suppress motor nerve terminal sprouting in our experiments. The paraproteinaemia might be completely unrelated to the patient's neuromuscular disease, or it might have caused the neuromuscular disease by a mechanism unrelated to the trophic system responsible for motor nerve terminal sprouting. It is also possible that the paraprotein is a monoclonal immunoglobulin which recognises determinants which are present on motor nerve growth factor or its receptor in man but not mice.
